JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Phase 1

Withdrawn

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: JNJ-56022473
Drug: Placebo

First Posted Date: 2016-09-30

Last Posted Date: 2017-11-27

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT02920424

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany

A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo (Intranasal)
Drug: Esketamine
Other: Alcohol
Drug: Placebo (Oral)

First Posted Date: 2016-09-29

Last Posted Date: 2019-04-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 27

Registration Number: NCT02919579

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: JNJ-63723283

First Posted Date: 2016-09-21

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 413

Registration Number: NCT02908906

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: JNJ-809
Drug: Apalutamide

First Posted Date: 2016-09-20

Last Posted Date: 2016-11-22

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT02906605

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Guselkumab
Drug: Placebo

First Posted Date: 2016-09-19

Last Posted Date: 2018-10-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 78

Registration Number: NCT02905331

Locations: 🇨🇦
Dr. Chih-ho Hong Medical, Surrey, British Columbia, Canada
🇨🇦
Dermatrials Research, Hamilton, Ontario, Canada
🇵🇱
Niepubliczny Zaklad Opieki Zdrowotnej Osteo-Medic s.c. Artur Racewicz i Jerzy Supronik, Bialystok, Poland

and more 11 locations

A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Withdrawn

Conditions: Prostatic Neoplasms

First Posted Date: 2016-09-19

Last Posted Date: 2017-02-08

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT02905201

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: JNJ-54175446, 600 mg
Drug: JNJ-54175446, 150 mg
Other: Placebo

First Posted Date: 2016-09-16

Last Posted Date: 2022-05-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 70

Registration Number: NCT02902601

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: AL-335

First Posted Date: 2016-09-09

Last Posted Date: 2017-12-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT02894905

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Odalasvir 100 mg
Drug: Placebo
Drug: Odalasvir 500 mg
Drug: Odalasvir (Up to maximum 1000 mg)

First Posted Date: 2016-09-05

Last Posted Date: 2017-04-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 60

Registration Number: NCT02889367

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Drospirenone/ethinylestradiol
Drug: AL-335
Drug: Odalasvir (ODV)
Drug: Simeprevir (SMV)

First Posted Date: 2016-08-31

Last Posted Date: 2017-01-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT02885454

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy